282 related articles for article (PubMed ID: 21827418)
1. Bioenergetics pathways and therapeutic resistance in gliomas: emerging role of mitochondria.
Griguer CE; Oliva CR
Curr Pharm Des; 2011; 17(23):2421-7. PubMed ID: 21827418
[TBL] [Abstract][Full Text] [Related]
2. Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
Lee CAA; Banerjee P; Wilson BJ; Wu S; Guo Q; Berg G; Karpova S; Mishra A; Lian JW; Tran J; Emmerich M; Murphy GF; Frank MH; Frank NY
J Biol Chem; 2020 May; 295(22):7774-7788. PubMed ID: 32317280
[TBL] [Abstract][Full Text] [Related]
3. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.
Agarwal S; Sane R; Oberoi R; Ohlfest JR; Elmquist WF
Expert Rev Mol Med; 2011 May; 13():e17. PubMed ID: 21676290
[TBL] [Abstract][Full Text] [Related]
4. Mitochondria and cancer chemoresistance.
Guerra F; Arbini AA; Moro L
Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):686-699. PubMed ID: 28161329
[TBL] [Abstract][Full Text] [Related]
5. Adaptive mitochondrial reprogramming and resistance to PI3K therapy.
Ghosh JC; Siegelin MD; Vaira V; Faversani A; Tavecchio M; Chae YC; Lisanti S; Rampini P; Giroda M; Caino MC; Seo JH; Kossenkov AV; Michalek RD; Schultz DC; Bosari S; Languino LR; Altieri DC
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25650317
[TBL] [Abstract][Full Text] [Related]
6. MiR-200c-based metabolic modulation in glioblastoma cells as a strategy to overcome tumor chemoresistance.
Cardoso AM; Morais CM; Sousa M; Rebelo O; Tão H; Barbosa M; Pedroso de Lima MC; Jurado AS
Hum Mol Genet; 2021 Nov; 30(23):2315-2331. PubMed ID: 34245265
[TBL] [Abstract][Full Text] [Related]
7. Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
Rieger L; Rieger J; Winter S; Streffer J; Esser P; Dichgans J; Meyermann R; Weller M
Acta Neuropathol; 2000 May; 99(5):555-62. PubMed ID: 10805101
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds.
Guntuku L; Naidu VG; Yerra VG
Curr Neuropharmacol; 2016; 14(6):567-83. PubMed ID: 26791479
[TBL] [Abstract][Full Text] [Related]
9. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
Mao H; Lebrun DG; Yang J; Zhu VF; Li M
Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
[TBL] [Abstract][Full Text] [Related]
10. Alantolactone induces apoptosis in glioblastoma cells via GSH depletion, ROS generation, and mitochondrial dysfunction.
Khan M; Yi F; Rasul A; Li T; Wang N; Gao H; Gao R; Ma T
IUBMB Life; 2012 Sep; 64(9):783-94. PubMed ID: 22837216
[TBL] [Abstract][Full Text] [Related]
11. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.
Datta S; Sears T; Cortopassi G; Woolard K; Angelastro JM
Biomed Pharmacother; 2021 Jan; 133():111058. PubMed ID: 33378970
[TBL] [Abstract][Full Text] [Related]
12. Dual-targeting of aberrant glucose metabolism in glioblastoma.
Shen H; Decollogne S; Dilda PJ; Hau E; Chung SA; Luk PP; Hogg PJ; McDonald KL
J Exp Clin Cancer Res; 2015 Feb; 34(1):14. PubMed ID: 25652202
[TBL] [Abstract][Full Text] [Related]
13. The pro-tumorigenic effects of metabolic alterations in glioblastoma including brain tumor initiating cells.
Landis CJ; Tran AN; Scott SE; Griguer C; Hjelmeland AB
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):175-188. PubMed ID: 29378228
[TBL] [Abstract][Full Text] [Related]
14. Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain.
Oliva CR; Nozell SE; Diers A; McClugage SG; Sarkaria JN; Markert JM; Darley-Usmar VM; Bailey SM; Gillespie GY; Landar A; Griguer CE
J Biol Chem; 2010 Dec; 285(51):39759-67. PubMed ID: 20870728
[TBL] [Abstract][Full Text] [Related]
15. Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance.
Polewski MD; Reveron-Thornton RF; Cherryholmes GA; Marinov GK; Cassady K; Aboody KS
Mol Cancer Res; 2016 Dec; 14(12):1229-1242. PubMed ID: 27658422
[TBL] [Abstract][Full Text] [Related]
16. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
17. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma.
Haga S; Hinoshita E; Ikezaki K; Fukui M; Scheffer GL; Uchiumi T; Kuwano M
Jpn J Cancer Res; 2001 Feb; 92(2):211-9. PubMed ID: 11223551
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial Lon is over-expressed in high-grade gliomas, and mediates hypoxic adaptation: potential role of Lon as a therapeutic target in glioma.
Di K; Lomeli N; Wood SD; Vanderwal CD; Bota DA
Oncotarget; 2016 Nov; 7(47):77457-77467. PubMed ID: 27764809
[TBL] [Abstract][Full Text] [Related]
20. CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
Maciaczyk D; Picard D; Zhao L; Koch K; Herrera-Rios D; Li G; Marquardt V; Pauck D; Hoerbelt T; Zhang W; Ouwens DM; Remke M; Jiang T; Steiger HJ; Maciaczyk J; Kahlert UD
Br J Cancer; 2017 Jun; 117(1):102-112. PubMed ID: 28571041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
